Mediwound's nexobrid® highlighted in 20 oral and poster presentations at the 20th european burns association congress

Yavne, israel, sept. 11, 2023 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th european burns association (eba) congress held in nantes, france on september 6-9, 2023.
MDWD Ratings Summary
MDWD Quant Ranking